Amgen Inc. in 3 stories
The narratives AMGN currently appears in, with its side and exposure in each.
Bull side
1 story- GLP-1 Eats Everything
AMGN in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
MariTide gives Amgen a differentiated, long-acting obesity candidate that could capture meaningful share of the expanding GLP-1 market.
Bear side
2 stories- America Imports the World's Drug Prices
AMGN in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Although Amgen sells biosimilars, its larger innovative-biologics franchise leaves it a net loser from lower benchmarked prices and reduced blockbuster value.
- The Patent Cliff Sparks a Biotech Land Grab
AMGN in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Amgen faces mature-product pressure and carries greater balance-sheet constraints after using a large acquisition to replenish growth.